STOCK TITAN

[Form 4] Agios Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

James William Burns, Chief Legal Officer of Agios Pharmaceuticals (AGIO), reported significant insider transactions on June 24, 2025:

  • Acquired 6,000 shares through the vesting of Performance Share Units (PSUs) at $0 exercise price
  • Subsequently sold 2,799 shares at $33.54 per share to cover tax withholding obligations
  • Following these transactions, Burns now directly owns 28,650 shares

The PSUs were originally granted on March 1, 2023, with 50% vesting upon achievement of a research milestone and 50% upon a regulatory milestone. The reported transaction reflects the vesting of the first 50% as the research milestone was met. The share sale was executed under a pre-established Rule 10b5-1 trading plan, providing an affirmative defense against insider trading liability.

James William Burns, Chief Legal Officer di Agios Pharmaceuticals (AGIO), ha riportato importanti operazioni di insider trading il 24 giugno 2025:

  • Ha acquisito 6.000 azioni tramite il vesting di Performance Share Units (PSU) con prezzo di esercizio pari a 0$
  • Ha successivamente venduto 2.799 azioni a 33,54$ per azione per coprire le obbligazioni fiscali
  • Dopo queste operazioni, Burns possiede direttamente 28.650 azioni

Le PSU erano state originariamente assegnate il 1 marzo 2023, con il 50% che si sarebbe maturato al raggiungimento di un obiettivo di ricerca e il restante 50% al raggiungimento di un obiettivo regolatorio. La transazione riportata riflette il vesting del primo 50% in quanto l'obiettivo di ricerca è stato raggiunto. La vendita delle azioni è stata effettuata nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, che offre una difesa affermativa contro la responsabilità per insider trading.

James William Burns, Director Legal de Agios Pharmaceuticals (AGIO), reportó transacciones significativas de información privilegiada el 24 de junio de 2025:

  • Adquirió 6,000 acciones mediante la consolidación de Unidades de Acciones de Desempeño (PSUs) con un precio de ejercicio de $0
  • Posteriormente vendió 2,799 acciones a $33.54 por acción para cubrir obligaciones fiscales
  • Tras estas operaciones, Burns posee directamente 28,650 acciones

Las PSUs fueron otorgadas originalmente el 1 de marzo de 2023, con un 50% consolidándose al alcanzar un hito de investigación y el otro 50% al lograr un hito regulatorio. La transacción reportada refleja la consolidación del primer 50% tras cumplirse el hito de investigación. La venta de acciones se realizó bajo un plan de trading preestablecido conforme a la Regla 10b5-1, que proporciona una defensa afirmativa contra la responsabilidad por uso de información privilegiada.

제임스 윌리엄 번스, Agios Pharmaceuticals(AGIO)의 최고 법률 책임자는 2025년 6월 24일 중요한 내부자 거래를 보고했습니다:

  • 행사가격 $0인 성과 주식 단위(PSU) 베스팅을 통해 6,000주를 취득
  • 세금 원천징수 의무를 충당하기 위해 2,799주를 주당 $33.54에 매도
  • 이 거래 이후 번스는 직접 28,650주를 보유하게 됨

PSU는 2023년 3월 1일에 처음 부여되었으며, 50%는 연구 성과 달성 시, 나머지 50%는 규제 성과 달성 시 베스팅됩니다. 보고된 거래는 연구 성과 달성으로 첫 50% 베스팅을 반영합니다. 주식 매도는 내부자 거래 책임에 대한 긍정적 방어를 제공하는 사전 설정된 규칙 10b5-1 거래 계획에 따라 실행되었습니다.

James William Burns, Chief Legal Officer d'Agios Pharmaceuticals (AGIO), a déclaré des transactions d'initiés importantes le 24 juin 2025 :

  • A acquis 6 000 actions suite à la levée de Performance Share Units (PSU) avec un prix d'exercice de 0 $
  • A ensuite vendu 2 799 actions à 33,54 $ par action pour couvrir ses obligations fiscales
  • Après ces transactions, Burns détient désormais directement 28 650 actions

Les PSU avaient été initialement attribuées le 1er mars 2023, avec 50 % acquises à l’atteinte d’un jalon de recherche et 50 % à un jalon réglementaire. La transaction rapportée reflète la levée des premiers 50 % suite à la réalisation du jalon de recherche. La vente des actions a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 préétabli, offrant une défense affirmative contre la responsabilité liée au délit d’initié.

James William Burns, Chief Legal Officer von Agios Pharmaceuticals (AGIO), meldete am 24. Juni 2025 bedeutende Insidertransaktionen:

  • Erwarb 6.000 Aktien durch die Vesting von Performance Share Units (PSUs) zum Ausübungspreis von 0 $
  • Verkaufte anschließend 2.799 Aktien zu je 33,54 $, um Steuerverpflichtungen zu decken
  • Nach diesen Transaktionen besitzt Burns nun direkt 28.650 Aktien

Die PSUs wurden ursprünglich am 1. März 2023 gewährt, wobei 50 % bei Erreichen eines Forschungserfolgs und 50 % bei Erreichen eines regulatorischen Meilensteins vesteten. Die gemeldete Transaktion spiegelt das Vesting der ersten 50 % wider, da der Forschungsmeilenstein erreicht wurde. Der Aktienverkauf erfolgte im Rahmen eines vorab eingerichteten Rule 10b5-1 Handelsplans, der eine positive Verteidigung gegen Insiderhandelshaftung bietet.

Positive
  • Performance milestone achievement: Company met specified research milestone, triggering 50% vesting of PSUs, indicating successful R&D progress
Negative
  • None.

James William Burns, Chief Legal Officer di Agios Pharmaceuticals (AGIO), ha riportato importanti operazioni di insider trading il 24 giugno 2025:

  • Ha acquisito 6.000 azioni tramite il vesting di Performance Share Units (PSU) con prezzo di esercizio pari a 0$
  • Ha successivamente venduto 2.799 azioni a 33,54$ per azione per coprire le obbligazioni fiscali
  • Dopo queste operazioni, Burns possiede direttamente 28.650 azioni

Le PSU erano state originariamente assegnate il 1 marzo 2023, con il 50% che si sarebbe maturato al raggiungimento di un obiettivo di ricerca e il restante 50% al raggiungimento di un obiettivo regolatorio. La transazione riportata riflette il vesting del primo 50% in quanto l'obiettivo di ricerca è stato raggiunto. La vendita delle azioni è stata effettuata nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, che offre una difesa affermativa contro la responsabilità per insider trading.

James William Burns, Director Legal de Agios Pharmaceuticals (AGIO), reportó transacciones significativas de información privilegiada el 24 de junio de 2025:

  • Adquirió 6,000 acciones mediante la consolidación de Unidades de Acciones de Desempeño (PSUs) con un precio de ejercicio de $0
  • Posteriormente vendió 2,799 acciones a $33.54 por acción para cubrir obligaciones fiscales
  • Tras estas operaciones, Burns posee directamente 28,650 acciones

Las PSUs fueron otorgadas originalmente el 1 de marzo de 2023, con un 50% consolidándose al alcanzar un hito de investigación y el otro 50% al lograr un hito regulatorio. La transacción reportada refleja la consolidación del primer 50% tras cumplirse el hito de investigación. La venta de acciones se realizó bajo un plan de trading preestablecido conforme a la Regla 10b5-1, que proporciona una defensa afirmativa contra la responsabilidad por uso de información privilegiada.

제임스 윌리엄 번스, Agios Pharmaceuticals(AGIO)의 최고 법률 책임자는 2025년 6월 24일 중요한 내부자 거래를 보고했습니다:

  • 행사가격 $0인 성과 주식 단위(PSU) 베스팅을 통해 6,000주를 취득
  • 세금 원천징수 의무를 충당하기 위해 2,799주를 주당 $33.54에 매도
  • 이 거래 이후 번스는 직접 28,650주를 보유하게 됨

PSU는 2023년 3월 1일에 처음 부여되었으며, 50%는 연구 성과 달성 시, 나머지 50%는 규제 성과 달성 시 베스팅됩니다. 보고된 거래는 연구 성과 달성으로 첫 50% 베스팅을 반영합니다. 주식 매도는 내부자 거래 책임에 대한 긍정적 방어를 제공하는 사전 설정된 규칙 10b5-1 거래 계획에 따라 실행되었습니다.

James William Burns, Chief Legal Officer d'Agios Pharmaceuticals (AGIO), a déclaré des transactions d'initiés importantes le 24 juin 2025 :

  • A acquis 6 000 actions suite à la levée de Performance Share Units (PSU) avec un prix d'exercice de 0 $
  • A ensuite vendu 2 799 actions à 33,54 $ par action pour couvrir ses obligations fiscales
  • Après ces transactions, Burns détient désormais directement 28 650 actions

Les PSU avaient été initialement attribuées le 1er mars 2023, avec 50 % acquises à l’atteinte d’un jalon de recherche et 50 % à un jalon réglementaire. La transaction rapportée reflète la levée des premiers 50 % suite à la réalisation du jalon de recherche. La vente des actions a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 préétabli, offrant une défense affirmative contre la responsabilité liée au délit d’initié.

James William Burns, Chief Legal Officer von Agios Pharmaceuticals (AGIO), meldete am 24. Juni 2025 bedeutende Insidertransaktionen:

  • Erwarb 6.000 Aktien durch die Vesting von Performance Share Units (PSUs) zum Ausübungspreis von 0 $
  • Verkaufte anschließend 2.799 Aktien zu je 33,54 $, um Steuerverpflichtungen zu decken
  • Nach diesen Transaktionen besitzt Burns nun direkt 28.650 Aktien

Die PSUs wurden ursprünglich am 1. März 2023 gewährt, wobei 50 % bei Erreichen eines Forschungserfolgs und 50 % bei Erreichen eines regulatorischen Meilensteins vesteten. Die gemeldete Transaktion spiegelt das Vesting der ersten 50 % wider, da der Forschungsmeilenstein erreicht wurde. Der Aktienverkauf erfolgte im Rahmen eines vorab eingerichteten Rule 10b5-1 Handelsplans, der eine positive Verteidigung gegen Insiderhandelshaftung bietet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burns James William

(Last) (First) (Middle)
88 SIDNEY STREET

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 06/24/2025 M 6,000 A $0 31,449 D
Common stock 06/24/2025 S(1) 2,799 D $33.54 28,650 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance share units (2) 06/24/2025 M 6,000 (3) (3) Common stock 6,000 $0 6,000 D
Explanation of Responses:
1. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023.
2. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
3. The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Remarks:
/s/ William Cook, as Attorney in Fact for James Burns 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at AGIO on June 24, 2025?

James William Burns, AGIO's Chief Legal Officer, acquired 6,000 shares through performance share units (PSUs) vesting and subsequently sold 2,799 shares at $33.54 per share to cover tax withholding obligations.

How many AGIO shares does James Burns own after the June 24, 2025 transactions?

Following the reported transactions, James Burns directly owns 28,650 shares of AGIO common stock.

What was the vesting trigger for AGIO's performance share units in June 2025?

The PSUs vested as to 50% of the underlying shares upon achievement of a specified research milestone, which was determined to have been met on June 24, 2025. The remaining 50% will vest upon achievement of a specified regulatory milestone.

Was AGIO's insider sale conducted under Rule 10b5-1?

Yes, the sale was executed pursuant to durable automatic sale instructions under Rule 10b5-1(c), which were included in the performance share unit agreement dated March 1, 2023, providing an affirmative defense to liability under Section 10(b).

What is the exercise price of AGIO's performance share units granted to James Burns?

The PSUs were granted with no exercise price ($0), with each PSU representing a contingent right to receive one share of AGIO's common stock upon meeting specified performance milestones.
Agios Pharmaceuticals Inc

NASDAQ:AGIO

AGIO Rankings

AGIO Latest News

AGIO Latest SEC Filings

AGIO Stock Data

1.93B
55.42M
1.52%
108.67%
6.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE